BioPharmSignal logoBioPharmSignal

Biotech News

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals (ARWR)Arrowhead PharmaceuticalsCompany update

PASADENA, Calif. --(BUSINESS WIRE)--Aug. 3, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 16, 2026, the Company’s Board of Directors approved “inducement” grants to 95 new employees under Rule

Related news

ARWRArrowhead Pharmaceuticals2026-08-04 20:01 EST

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

ARWRArrowhead Pharmaceuticals2026-08-04 20:00 EST

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher

ABEOAbeona Therapeutics2026-08-03 11:30 EST

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BCRXBioCryst Pharmaceuticals2026-07-02 11:00 EST

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTCTPTC Therapeutics, Inc.2026-06-17 20:30 EST

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MGTXMeiraGTx2026-08-06 20:30 EST

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RAREUltragenyx Pharmaceutical2026-07-24 20:30 EST

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RCKTRocket Pharmaceuticals2026-05-28 11:00 EST

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

RCKTRocket Pharmaceuticals2026-04-28 11:00 EST

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

ETONEton Pharmaceuticals2026-05-19 20:30 EST

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)

View all latest news

Arrowhead Pharmaceuticals

RNA Interference Platform Arrowhead Pharmaceuticals develops RNA interference medicines that silence disease-causing genes. Its delivery technologies support programs targeting the liver and other tissues. REDEMPLO REDEMPLO, or plozasiran, is an RNAi therapy targeting APOC3. It is approved in the United States to reduce triglycerides in...

Recent company news

ARWRArrowhead Pharmaceuticals2026-08-04 20:01 EST

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

ARWRArrowhead Pharmaceuticals2026-08-04 20:00 EST

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher

ARWRArrowhead Pharmaceuticals2026-08-03 20:30 EST

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

ARWRArrowhead Pharmaceuticals2026-07-27 11:30 EST

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

ARWRArrowhead Pharmaceuticals2026-07-22 11:30 EST

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia

Stock data

Close
85.83 USD
Market cap
9.98B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States